Wallaby Medical Holding, Inc. (referred to as "Wallaby Medical" below) was established in December 2015, with a focus on developing innovative, breakthrough, and clinically validated technologies and solutions for the treatment of neurovascular diseases.The vision of the company is to "save more lives impacted by stroke."

In April 2022, Wallaby Medical successfully acquired phenox GmbH (hereinafter referred to as "phenox"), a leading global neurointerventional company based in Germany. Following the acquisition, Wallaby Medical holds a complete and globally competitive portfolio of neurointerventional products, with 5 R&D centers, 3 production bases, over 700 employees worldwide.